Qiang Zhang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Qiang Zhang has a total of 176 co-authors. Here are the top co-authors by number of shared publications:
- Stefan Kazimierz Piechnik
Oxford Centre for Clinical Magnetic Resonance Research (OCMR), John Radcliffe Hospital, National Institute for Health Research (NIHR) Oxford Biomedical Research Centre, Oxford BHF Centre of Research Excellence, University of Oxford, Oxford, United Kingdom
9 shared publications - Vanessa M. Ferreira
Oxford Centre for Clinical Magnetic Resonance Research (OCMR), John Radcliffe Hospital, National Institute for Health Research (NIHR) Oxford Biomedical Research Centre, Oxford BHF Centre of Research Excellence, University of Oxford, Oxford, United Kingdom
9 shared publications - Di Zhou
Department of Magnetic Resonance Imaging, Fuwai Hospital, State Key Laboratory of Cardiovascular Disease, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
8 shared publications - Minjie Lu
Department of Magnetic Resonance Imaging, Fuwai Hospital and National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College , Beilishi Road No. 167, Xicheng District, Beijing 100037
8 shared publications - Yining Wang
Department of Magnetic Resonance Imaging, Fuwai Hospital, State Key Laboratory of Cardiovascular Disease, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
7 shared publications - Huaying Zhang
Department of Magnetic Resonance Imaging, Fuwai Hospital, State Key Laboratory of Cardiovascular Disease, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, No. 167 North Lishi Rd, Xicheng District, Beijing 100037, China
6 shared publications
Latest Publications
- 1 October 2026
- Published by Radiological Society of North America (RSNA) in Radiology
- Vol. 321 (1)
Myocardial T1 Mapping at 3 T: A Comparison of MOLLI and ShMOLLI across Healthy Volunteers and Various Cardiovascular Pathologies
In participants who underwent 3-T cardiac MRI with both modified Look-Locker inversion recovery (MOLLI) and shortened MOLLI (ShMOLLI) sequences, native T1 was higher with MOLLI than ShMOLLI, but extracellular volume fraction was consistent across sequences.
- 1 October 2026
- Published by Radiological Society of North America (RSNA) in Radiology
- Vol. 321 (1)
Myocardial T1 Mapping at 3 T: A Comparison of MOLLI and ShMOLLI across Healthy Volunteers and Various Cardiovascular Pathologies
In participants who underwent 3-T cardiac MRI with both modified Look-Locker inversion recovery (MOLLI) and shortened MOLLI (ShMOLLI) sequences, native T1 was higher with MOLLI than ShMOLLI, but extracellular volume fraction was consistent across sequences.
- Open Access
- 31 August 2026
- Published by Oxford University Press (OUP) in European Heart Journal
Mapping organ fat distribution and body composition: towards precision profiling of cardiometabolic disease risk
Background and Aims: Adiposity exerts multisystem insults across multiple organs and physiological pathways. This underscores the need for a systems-level framework integrating key organ fat measurements to disentangle the heterogeneous pathways through which adiposity shapes differential cardiometabolic risk profiles. Such an approach could advance mechanistic understanding and enable more precise risk stratification. Methods: In the UK Biobank, 24 935 participants without overt cardiac disease were studied. Six adiposity phenotypic groups were identified using unsupervised clustering of MRI-derived adiposity measures (subcutaneous, visceral, pericardial, liver, pancreatic, and muscle fat). These phenotypes were characterized in terms of body composition, cardiac remodelling, and the development of major cardiometabolic diseases. Results: Each phenotype showed a distinct pattern of fat distribution and body composition. A pancreatic-fat dominant phenotype, marked by visceral adiposity and sarcopenic features, showed a cardiorenal-metabolic risk profile. A muscle-fat dominant phenotype, characterized by subcutaneous adiposity and sarcopenic features, was associated with increased heart failure risk. While pericardial-fat dominant and liver-fat dominant phenotypes did not associate with cardiac disease risk, they exhibited distinctive cardiac remodelling patterns, revealing phenotype-specific metabolic-cardiac interactions. Lastly, normal-weight individuals with mild multi-organ fat showed elevated chronic ischaemic heart disease risk, highlighting the value of phenotype-based risk assessment beyond general weight measures. Conclusions: Distinct patterns of multi-organ fat accumulation were associated with differential body composition, cardiac remodelling, and cardiometabolic disease risk profiles. The identified adiposity phenotypic groups capture clinically meaningful heterogeneity across the cardiorenal-metabolic spectrum and may inform future personalized, multisystem approaches to prevention and management.
- 31 August 2026
- Published by Oxford University Press (OUP) in European Heart Journal
Open AccessMapping organ fat distribution and body composition: towards precision profiling of cardiometabolic disease risk
Background and Aims: Adiposity exerts multisystem insults across multiple organs and physiological pathways. This underscores the need for a systems-level framework integrating key organ fat measurements to disentangle the heterogeneous pathways through which adiposity shapes differential cardiometabolic risk profiles. Such an approach could advance mechanistic understanding and enable more precise risk stratification. Methods: In the UK Biobank, 24 935 participants without overt cardiac disease were studied. Six adiposity phenotypic groups were identified using unsupervised clustering of MRI-derived adiposity measures (subcutaneous, visceral, pericardial, liver, pancreatic, and muscle fat). These phenotypes were characterized in terms of body composition, cardiac remodelling, and the development of major cardiometabolic diseases. Results: Each phenotype showed a distinct pattern of fat distribution and body composition. A pancreatic-fat dominant phenotype, marked by visceral adiposity and sarcopenic features, showed a cardiorenal-metabolic risk profile. A muscle-fat dominant phenotype, characterized by subcutaneous adiposity and sarcopenic features, was associated with increased heart failure risk. While pericardial-fat dominant and liver-fat dominant phenotypes did not associate with cardiac disease risk, they exhibited distinctive cardiac remodelling patterns, revealing phenotype-specific metabolic-cardiac interactions. Lastly, normal-weight individuals with mild multi-organ fat showed elevated chronic ischaemic heart disease risk, highlighting the value of phenotype-based risk assessment beyond general weight measures. Conclusions: Distinct patterns of multi-organ fat accumulation were associated with differential body composition, cardiac remodelling, and cardiometabolic disease risk profiles. The identified adiposity phenotypic groups capture clinically meaningful heterogeneity across the cardiorenal-metabolic spectrum and may inform future personalized, multisystem approaches to prevention and management.
- 1 July 2026
- Published by Radiological Society of North America (RSNA) in Radiology
- Vol. 320 (1)
SCAN-MRI: Cardiac MRI–integrated Risk Score for Predicting Cardiovascular Events in Type 2 Diabetes Mellitus
A cardiac MRI-based multivariable risk model, integrating clinical factors and MRI parameters, demonstrated good discrimination and better performance than current established risk models in predicting adverse outcomes in participants with diabetes mellitus.
- 1 July 2026
- Published by Radiological Society of North America (RSNA) in Radiology
- Vol. 320 (1)
SCAN-MRI: Cardiac MRI–integrated Risk Score for Predicting Cardiovascular Events in Type 2 Diabetes Mellitus
A cardiac MRI-based multivariable risk model, integrating clinical factors and MRI parameters, demonstrated good discrimination and better performance than current established risk models in predicting adverse outcomes in participants with diabetes mellitus.
- 1 April 2026
- Published by Radiological Society of North America (RSNA) in Radiology: Cardiothoracic Imaging
- Vol. 8 (2) , e250476
Quantifying the Spectrum of Myocardial Fibrosis with Cardiovascular MRI: A Histopathologic Validation Study in Swine
Cardiac MRI T1 mapping enabled sensitive and accurate detection of low-grade myocardial fibrosis in a histopathologic examination–validated swine model of chronic myocardial infarction.
- 1 April 2026
- Published by Radiological Society of North America (RSNA) in Radiology: Cardiothoracic Imaging
- Vol. 8 (2) , e250476
Quantifying the Spectrum of Myocardial Fibrosis with Cardiovascular MRI: A Histopathologic Validation Study in Swine
Cardiac MRI T1 mapping enabled sensitive and accurate detection of low-grade myocardial fibrosis in a histopathologic examination–validated swine model of chronic myocardial infarction.
- 1 September 2025
- Published by Radiological Society of North America (RSNA) in Radiology
- Vol. 316 (3) , e243427
Risk Stratification of Sudden Cardiac Death in Nonischemic Dilated Cardiomyopathy: Arrhythmogenic Substrate Assessment in Cardiac MRI
The authors developed a comprehensive workflow for cardiac MRI-based evaluation of sudden cardiac death risk in patients with nonischemic dilated cardiomyopathy, aimed at improving personalized prognostic assessment for individualized patient care and management.
- 1 September 2025
- Published by Radiological Society of North America (RSNA) in Radiology
- Vol. 316 (3) , e243427
Risk Stratification of Sudden Cardiac Death in Nonischemic Dilated Cardiomyopathy: Arrhythmogenic Substrate Assessment in Cardiac MRI
The authors developed a comprehensive workflow for cardiac MRI-based evaluation of sudden cardiac death risk in patients with nonischemic dilated cardiomyopathy, aimed at improving personalized prognostic assessment for individualized patient care and management.
- 1 June 2025
- Published by Radiological Society of North America (RSNA) in Radiology
- Vol. 315 (3) , e243080
Right Ventricular Strain Improves Cardiac MRI–based Prognostication in Heart Failure with Preserved Ejection Fraction
Right ventricular global longitudinal and circumferential strain derived from cardiac MRI were independently associated with adverse outcomes in a large cohort of patients with heart failure with preserved ejection fraction.
- 1 June 2025
- Published by Radiological Society of North America (RSNA) in Radiology
- Vol. 315 (3) , e243080
Right Ventricular Strain Improves Cardiac MRI–based Prognostication in Heart Failure with Preserved Ejection Fraction
Right ventricular global longitudinal and circumferential strain derived from cardiac MRI were independently associated with adverse outcomes in a large cohort of patients with heart failure with preserved ejection fraction.
- Open Access
- 1 March 2025
- Published by Wolters Kluwer Health in Circulation: Cardiovascular Imaging
- Vol. 18 (3) , e017246
Prognosis and Risk Stratification in Dilated Cardiomyopathy With LVEF≤35%: Cardiac MRI Insights for Better Outcomes
BACKGROUND: Current guidelines recommend implantable cardioverter defibrillators for the primary prevention of sudden cardiac death (SCD) in patients with dilated cardiomyopathy with left ventricular ejection fraction (LVEF)≤35%. However, its effectiveness is hindered by the inability to reliably discriminate between the risk of SCD and competing death of heart failure deterioration, thereby limiting its clinical utility. We aimed to refine the SCD risk stratification model based on cardiac magnetic resonance imaging for patients with dilated cardiomyopathy with LVEF≤35%. METHODS: A total of 1272 patients with dilated cardiomyopathy with LVEF≤35% who underwent cardiac magnetic resonance imaging were consecutively enrolled in this study. The primary end point is a composite of SCD or aborted SCD and the second end point is a composite of heart failure death and heart transplantation. RESULTS: Over a median follow-up of 86.3 months, 101 patients reached the primary end point. In the adjusted analysis, age (hazard ratio [HR], 1.02 [95% CI, 1.01–1.04]; P =0.006) years, a family history of SCD (HR, 2.00 [95% CI, 1.01–3.98]; P =0.05), NT-proBNP (N-terminal pro-B-type natriuretic peptide) (HR, 2.02 [95% CI, 1.18–3.44]; P =0.01), LVEF (per 5% HR, 0.79 [95% CI, 0.66–0.95]; P =0.01), and late gadolinium enhancement≥7.5% (HR, 4.11[95% CI, 2.72–6.21]; P 2 was an independent predictor of the secondary end point (adjusted HR, 1.65 [95% CI, 1.13–2.40]; P =0.009). Compared with late gadolinium enhancement<7.5%, patients with late gadolinium enhancement≥7.5% and LVEF≤20% had a 7.12-fold higher risk of experiencing SCD events in competing Cox analysis (annual event rate, 4.8%). CONCLUSIONS: Patients with dilated cardiomyopathy with late gadolinium enhancement≥7.5% were at heightened risk of SCD events, which can be used for risk assessment. Risk stratifications for SCD, combining clinical and cardiac magnetic resonance imaging may potentially guide decision-making for implantable cardioverter defibrillator therapy.
- 1 March 2025
- Published by Wolters Kluwer Health in Circulation: Cardiovascular Imaging
- Vol. 18 (3) , e017246
Open AccessPrognosis and Risk Stratification in Dilated Cardiomyopathy With LVEF≤35%: Cardiac MRI Insights for Better Outcomes
BACKGROUND: Current guidelines recommend implantable cardioverter defibrillators for the primary prevention of sudden cardiac death (SCD) in patients with dilated cardiomyopathy with left ventricular ejection fraction (LVEF)≤35%. However, its effectiveness is hindered by the inability to reliably discriminate between the risk of SCD and competing death of heart failure deterioration, thereby limiting its clinical utility. We aimed to refine the SCD risk stratification model based on cardiac magnetic resonance imaging for patients with dilated cardiomyopathy with LVEF≤35%. METHODS: A total of 1272 patients with dilated cardiomyopathy with LVEF≤35% who underwent cardiac magnetic resonance imaging were consecutively enrolled in this study. The primary end point is a composite of SCD or aborted SCD and the second end point is a composite of heart failure death and heart transplantation. RESULTS: Over a median follow-up of 86.3 months, 101 patients reached the primary end point. In the adjusted analysis, age (hazard ratio [HR], 1.02 [95% CI, 1.01–1.04]; P =0.006) years, a family history of SCD (HR, 2.00 [95% CI, 1.01–3.98]; P =0.05), NT-proBNP (N-terminal pro-B-type natriuretic peptide) (HR, 2.02 [95% CI, 1.18–3.44]; P =0.01), LVEF (per 5% HR, 0.79 [95% CI, 0.66–0.95]; P =0.01), and late gadolinium enhancement≥7.5% (HR, 4.11[95% CI, 2.72–6.21]; P 2 was an independent predictor of the secondary end point (adjusted HR, 1.65 [95% CI, 1.13–2.40]; P =0.009). Compared with late gadolinium enhancement<7.5%, patients with late gadolinium enhancement≥7.5% and LVEF≤20% had a 7.12-fold higher risk of experiencing SCD events in competing Cox analysis (annual event rate, 4.8%). CONCLUSIONS: Patients with dilated cardiomyopathy with late gadolinium enhancement≥7.5% were at heightened risk of SCD events, which can be used for risk assessment. Risk stratifications for SCD, combining clinical and cardiac magnetic resonance imaging may potentially guide decision-making for implantable cardioverter defibrillator therapy.
- Open Access
Detection of Diffuse to Focal Myocardial Fibrosis by Cardiovascular Magnetic Resonance Against Histology in Mini-Swine
Background: Myocardial fibrosis predicts adverse outcomes in myocardial infarction (MI) and other cardiovascular conditions. Cardiovascular magnetic resonance (CMR) can non-invasively detect focal and diffuse myocardial fibrosis, but comprehensive validation against histology remains scarce. Aims: To assess the comparative diagnostic performance of CMR methods in detecting myocardial fibrosis, using a mini-swine model and histology as gold standard. Methods: Eighteen mini-swine (16 MI; 2 healthy) underwent CMR cine, LGE, T1- and ECV-mapping. Two commonly-used T1-mapping methods – MOLLI 5(3)3 and ShMOLLI 5(1)1(1)1 – were included. Pathological sections were categorized as infarcted, peri-infarct, remote and healthy myocardium based on triphenyl tetrazolium chloride staining. Fibrotic burden was quantified by collagen volume fraction (CVF) into severe (CVF≥30%), moderate (CVF=10-25%), and mild (CVF=3-14%). The relationships between LGE, T1, ECV and CVF, and diagnostic performance using area-under-the-curve (AUC), were analyzed. Results: For detecting severe fibrosis, LGE, T1 and ECV all had excellent diagnostic performance (AUC: LGE=0.93, ECV ShMOLLI =0.96, T1 ShMOLLI =0.91, T1 MOLLI =0.93, ECV MOLLI =0.88). ECV ShMOLLI showed significantly better discriminatory accuracy than ECV MOLLI in detecting severe fibrosis and MI (both pShMOLLI r=0.86, ECV MOLLI r=0.82, T1 ShMOLLI r=0.77, T1 MOLLI r=0.77, semi-quantitative LGE r=0.75). Only T1 ShMOLLI and ECV ShMOLLI , but not LGE or T1 MOLLI /ECV MOLLI , differentiated remote myocardium with mild fibrosis (CVF=8.23%) from healthy myocardium (CVF=2.01%). Conclusions: CMR can detect severe to mild myocardial fibrosis as validated against histology. For low-grade fibrosis, T1-mapping significantly outperformed LGE. Choice of CMR methodologies matters for myocardial fibrosis detection, which has importance for clinical trial design.
Open AccessDetection of Diffuse to Focal Myocardial Fibrosis by Cardiovascular Magnetic Resonance Against Histology in Mini-Swine
Background: Myocardial fibrosis predicts adverse outcomes in myocardial infarction (MI) and other cardiovascular conditions. Cardiovascular magnetic resonance (CMR) can non-invasively detect focal and diffuse myocardial fibrosis, but comprehensive validation against histology remains scarce. Aims: To assess the comparative diagnostic performance of CMR methods in detecting myocardial fibrosis, using a mini-swine model and histology as gold standard. Methods: Eighteen mini-swine (16 MI; 2 healthy) underwent CMR cine, LGE, T1- and ECV-mapping. Two commonly-used T1-mapping methods – MOLLI 5(3)3 and ShMOLLI 5(1)1(1)1 – were included. Pathological sections were categorized as infarcted, peri-infarct, remote and healthy myocardium based on triphenyl tetrazolium chloride staining. Fibrotic burden was quantified by collagen volume fraction (CVF) into severe (CVF≥30%), moderate (CVF=10-25%), and mild (CVF=3-14%). The relationships between LGE, T1, ECV and CVF, and diagnostic performance using area-under-the-curve (AUC), were analyzed. Results: For detecting severe fibrosis, LGE, T1 and ECV all had excellent diagnostic performance (AUC: LGE=0.93, ECV ShMOLLI =0.96, T1 ShMOLLI =0.91, T1 MOLLI =0.93, ECV MOLLI =0.88). ECV ShMOLLI showed significantly better discriminatory accuracy than ECV MOLLI in detecting severe fibrosis and MI (both pShMOLLI r=0.86, ECV MOLLI r=0.82, T1 ShMOLLI r=0.77, T1 MOLLI r=0.77, semi-quantitative LGE r=0.75). Only T1 ShMOLLI and ECV ShMOLLI , but not LGE or T1 MOLLI /ECV MOLLI , differentiated remote myocardium with mild fibrosis (CVF=8.23%) from healthy myocardium (CVF=2.01%). Conclusions: CMR can detect severe to mild myocardial fibrosis as validated against histology. For low-grade fibrosis, T1-mapping significantly outperformed LGE. Choice of CMR methodologies matters for myocardial fibrosis detection, which has importance for clinical trial design.
Exploring cardiovascular involvement in IgG4-related disease: a case series approach with cardiovascular magnetic resonance
Background: IgG4-related disease (IgG4-RD) is a relapsing–remitting, fibroinflammatory, multisystem disorder. Cardiovascular involvement from IgG4-RD has not been systematically characterised. In this study, we sought to evaluate consecutive patients with IgG4-RD using a detailed multiparametric cardiovascular magnetic resonance (CMR) imaging protocol. Methods: We prospectively enrolled 11 patients with histology-confirmed IgG4-RD; with active disease at time of scan. We undertook a detailed multiparametric CMR imaging protocol at 1.5T including cine imaging, native T1 and T2 mapping, stress perfusion imaging with inline quantitation of myocardial blood flow and late gadolinium enhancement (LGE) imaging. Results: All patients exhibited at least one abnormality on CMR imaging. Abnormal elevation of global or segmental left ventricular myocardial T1 and T2 values was present in four patients, suggesting myocardial oedema or inflammation. Abnormal LGE, suggesting myocardial scar fibrosis, was present in nine patients, with eight displaying a non-ischaemic pattern, and one showing an ischaemic pattern. Four patients fulfilled both Lake Louise Criteria for active myocardial inflammation, while a further six fulfilled one criterion. Myocardial perfusion reserve was normal in all evaluable patients. Ten patients had normal ventricular volumes, mass and systolic function. In addition, thoracic aortitis was identified in three patients who underwent 18 F-flourodeoxyglucose PET/CT imaging, with resolution following anti-B-cell treatment. Conclusions: In this cohort of patients with histology-confirmed IgG4-RD, multiparametric CMR revealed no changes in gross cardiac structure and function, but frequent myocardial tissue abnormalities. These data suggest a plausible pathophysiological link between IgG4-RD and cardiovascular involvement.
Exploring cardiovascular involvement in IgG4-related disease: a case series approach with cardiovascular magnetic resonance
Background: IgG4-related disease (IgG4-RD) is a relapsing–remitting, fibroinflammatory, multisystem disorder. Cardiovascular involvement from IgG4-RD has not been systematically characterised. In this study, we sought to evaluate consecutive patients with IgG4-RD using a detailed multiparametric cardiovascular magnetic resonance (CMR) imaging protocol. Methods: We prospectively enrolled 11 patients with histology-confirmed IgG4-RD; with active disease at time of scan. We undertook a detailed multiparametric CMR imaging protocol at 1.5T including cine imaging, native T1 and T2 mapping, stress perfusion imaging with inline quantitation of myocardial blood flow and late gadolinium enhancement (LGE) imaging. Results: All patients exhibited at least one abnormality on CMR imaging. Abnormal elevation of global or segmental left ventricular myocardial T1 and T2 values was present in four patients, suggesting myocardial oedema or inflammation. Abnormal LGE, suggesting myocardial scar fibrosis, was present in nine patients, with eight displaying a non-ischaemic pattern, and one showing an ischaemic pattern. Four patients fulfilled both Lake Louise Criteria for active myocardial inflammation, while a further six fulfilled one criterion. Myocardial perfusion reserve was normal in all evaluable patients. Ten patients had normal ventricular volumes, mass and systolic function. In addition, thoracic aortitis was identified in three patients who underwent 18 F-flourodeoxyglucose PET/CT imaging, with resolution following anti-B-cell treatment. Conclusions: In this cohort of patients with histology-confirmed IgG4-RD, multiparametric CMR revealed no changes in gross cardiac structure and function, but frequent myocardial tissue abnormalities. These data suggest a plausible pathophysiological link between IgG4-RD and cardiovascular involvement.